Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Flagstar Bank NA (FLG) Price & Performance

ADMA Biologics Inc
Flagstar Bank NA

Price performance

Price movement over the last 24 hours

Key statistics

ADMA Biologics Inc vs Flagstar Bank NA — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Flagstar Bank NA trades at $14.43 (market cap $6.15B). The key difference: Flagstar Bank NA is far larger — about 2.9× ADMA Biologics Inc's market cap, and Flagstar Bank NA pays a 0.27% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAFLG
Market Cap
$2.13B$6.15B
Sector
HealthFinancials
52-Week High
$20.38$15.28
52-Week Low
$7.60$10.72
Enterprise Value
$2.20B
Dividend Yield
0.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Flagstar Bank NA

Flagstar Bank (FLG) trades at $14.84, up 1.71% today, showing technical bullish momentum with strong moving average signals. The company has delivered two consecutive quarterly earnings beats (Q4 2025 and Q1 2026) and recently announced a proprietary technology transformation. Despite negative profitability metrics, the stock trades below book value (P/B 0.81) and analysts maintain a 50/50 buy/hold split with a $16.94 consensus target.

FLG presents a turnaround story with improving fundamentals but carries execution risks. The bank's shift toward profitability and technology investments offers potential upside, though negative margins and high interest expenses remain concerns. With the current price below analyst targets, the stock offers value potential but requires careful monitoring of credit quality and operational improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Flagstar Bank NA

Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.

Read more on FLG